• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Specifics of registration of orphan drugs in Russia

14.04.2021/in Publications /by Marketing

It is believed that if a disease is rare, it is very difficult to meet it among patients, but collectively all “rare” patients constitute a huge population. For example, about 30 million patients with rare diseases are registered today in the European Union. Diagnostic methods of modern medicine are becoming more and more advanced, and with the development of science more and more rare diseases are revealed – on average 5 new pathologies become known every week. All in all, about 5-7 thousand rare diseases (congenital, hematological, oncological, autoimmune, and others) are known to date.

For the first time in the Russian legislation the definition of “orphan diseases” was given in 2011 in the Federal law “On the bases of health protection of citizens in the Russian Federation”. This document defines rare (orphan) diseases as diseases with the prevalence of no more than 10 cases per 100 thousand people (or 1 case per 10 thousand). According to various estimates, from 300 thousand to 5 million people are suffering from rare diseases in Russia. The lack of more precise statistics is because the concept of orphan diseases was introduced quite recently.

Moreover, in 2012 the Government of the Russian Federation approved the list of life-threatening and chronic progressive rare (orphan) diseases, leading to reduction of life expectancy of citizens or their disability, represented by 24 nosologies and placed in open access on the official Internet portal of legal information (pravo.gov.ru). Also approved were the rules for maintaining the Federal register of persons suffering from rare (orphan) diseases designated in the list.

According to Federal Law No. 61-FZ dated April 12, 2010 orphan drugs intended exclusively for diagnostics or pathogenetic treatment (treatment aimed at the mechanism of disease development) of rare (orphan) diseases are referred to as orphan drugs.

Most drugs used to treat patients with orphan diseases have a very high cost, as they are created based on expensive biotechnologies, including the development of monoclonal antibodies, recombinant proteins, and other complex substances in production. It takes an average of about 10 years of work and about $1 billion of investment to create an innovative drug. If an innovative drug is developed to treat a mass disease and will be sold in large quantities, then the costs of its production will pay off. But in the case of orphan drugs, it’s different – there are very few patients worldwide, so the volume of sales will be very small, and the cost of each package, which is correspondingly expensive, will increase significantly.

Some manufacturers see no commercial benefit for themselves in the production of orphan drugs. Nevertheless, every year more and more of them appear on the international market. This is not the least since the production of such drugs in some countries is supported by benefits from the state. For example, in the U.S. there are tax benefits for manufacturers of orphan drugs. Besides, in the USA, Japan, and the EU countries, the producers of orphan drugs are provided special conditions for bringing the drug to the market considering its medical indications – within 10 (EU), 7 (USA), and 5 (Japan) years after bringing the drug to the market no more drugs will be registered for this indication. Such special conditions have been introduced since the development of orphan drugs takes longer (up to 15 years) than the development of other drugs, due to the long lead time to enroll patients in clinical trials.

In Russia, very important steps have also been made in this direction. Today there is a program called “7 Nosologies”, which allocates funds for the purchase of drugs for patients suffering from one of seven diseases that require treatment. Of these seven nosologies, four are rare diseases: hemophilia, cystic fibrosis, pituitary dwarfism, and Gaucher disease.

The “7 Nosologies” program has demonstrated good results in the treatment of patients with rare diseases. For example, the lives of patients suffering from hemophilia have improved dramatically. If before the disease led to their disability, fractures, they were limited in terms of ability to work and had a very low quality of life, now hemophilia, due to patients receiving modern medicines, is treated very effectively, allowing patients to lead a full life.

Of great importance in funding the treatment of patients with orphan diseases worldwide, including in Russia, are charitable and patient organizations that bring together patients with a particular rare disease. Since 2008, the last day of February has been declared Rare Diseases Day, which emphasizes the public importance of the problem of treating these diseases.

An important part of the support for manufacturers is an accelerated procedure for expert examination of orphan drugs for state registration (Article 26 of Federal Law 61). The accelerated expert examination procedure for orphan drugs is conducted by a decision of the corresponding authorized federal executive body based on the applicant’s application, within a period not exceeding eighty business days. Expert examination of the documents contained in the registration dossier for a medicinal product shall be conducted within a period not exceeding ten business days. Expert examination of the quality of a medicinal product and expert examination of the ratio of the expected benefit to the possible risk of using the medicinal product shall be conducted within no more than sixty business days.

For orphan drugs, results of preclinical and clinical studies performed outside the Russian Federation by the rules of good laboratory practice and the rules of good clinical practice may be submitted.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Corrections to clinical trial documents due to COVID-19. Russian experience.
Read More
Publications
WHAT IS BIOEQUIVALENCE
Read More
Publications
THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

4 + 0 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Specifics of conducting pediatric clinical trials with children in Russia Bioequivalence studies during the COVID-19 pandemic. Russian experience.
Scroll to top